Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...
IDEAYA Biosciences’ $175 Million Common Stock Public Offering
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Merck’s Acquisition of Prometheus Biosciences
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
Harrow’s $100 Million Secured Credit Financing Agreement with Oaktree
Latham & Watkins advised Oaktree on the financing. Harrow (Nasdaq: HROW) announced that it has entered into a $100 million secured credit financing agreement with funds...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
Latham & Watkins Elects 23 New Partners
Latham & Watkins LLP is pleased to announce that 23 counsel have been elected to the partnership, effective March 1. The group brings tremendous experience, knowledge,...
Mineralys Therapeutics’ $192 Million Initial Public Offering
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
OPEN Health’s Acquisition of Acsel Health
Latham & Watkins LLP represented Astorg and OPEN Health in the transaction. OPEN Health, a portfolio company of European private equity firm Astorg, announced the acquisition of...
Natus’ Acquisition of Micromed Holding SAS
Latham & Watkins LLP represented ArchiMed and Natus in the transaction. Natus Medical Incorporated (Natus), a leading provider of medical device solutions, has announced the closing...
Alphatec Spine’s $200 Million Growth Financing Facilities
Latham & Watkins LLP represented Alphatec in the transactions. Alphatec Holdings, Inc. (Nasdaq: ATEC), a medical technology company focusing on surgical treatment for spinal disorders has...
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...